The Next GLP-1s: Orforglipron, Retatrutide, CagriSema, and the 2026–2028 Pipeline

The current market — semaglutide and tirzepatide, needles and one ritual-bound pill — is a snapshot, not an endpoint. Three late-stage programs will define the 2026–2028 landscape, and each answers a different weakness of the incumbents.

Orforglipron: approved — the pill without rules arrived

This one graduated from pipeline to pharmacy: the FDA approved orforglipron as Foundayo on April 1, 2026 — the first small-molecule GLP-1, a daily pill with no food, water, or timing restrictions, taken any time of day. ATTAIN-1 (3,127 adults) supported roughly 12.4% average weight loss at the highest dose over 72 weeks — below injectable semaglutide's 14.9% and well below tirzepatide's 20%+, but from an unrefrigerated, restriction-free tablet. Launch pricing did what small-molecule economics promised: $149/month self-pay at the lowest dose via LillyDirect (then retail and telehealth), $25 with commercial savings cards, and ~$50 Medicare Part D copays from July 1, 2026. The full clinical and buying guide: Foundayo, explained.

Retatrutide: phase 3 delivered the biggest numbers ever

Also Lilly's: a triple agonist (GLP-1 + GIP + glucagon receptors), and phase 3 confirmed the phase 2 promise loudly. TRIUMPH-4 (December 2025) averaged 28.7% at the 12 mg dose with knee-osteoarthritis pain relief; TRIUMPH-1 (May 2026, 2,339 adults) reached up to ~30.3% average loss over 80 weeks; TRIUMPH-2 and -3 (July 2026) added up to 20.8% in type 2 diabetes and 22.6% in established cardiovascular disease, and an OSA substudy showed a 60.6% AHI reduction. The asterisk analysts flagged: 11.3% high-dose discontinuation for adverse events versus 4.9% on placebo. Retatrutide remains investigational — the BLA is expected around Q1 2027, putting realistic approval in late 2027–2028 — but it is now the clearest ceiling-raiser over tirzepatide on record; the full readout-by-readout picture is in the retatrutide phase 3 guide.

CagriSema, and the muscle-preservation flank

Novo Nordisk's CagriSema — cagrilintide (an amylin analog) co-formulated with semaglutide — posted about 22.7% at 68 weeks in REDEFINE-1: a clear step past semaglutide alone, shy of the sky-high expectations, filed and advancing. Around these headliners, two flanking movements matter: amylin monotherapy and other novel mechanisms aiming at GLP-1-like results with gentler GI profiles, and muscle-preservation agents (myostatin/activin-pathway drugs) in trials specifically to pair with incretins — the pharmaceutical answer to the lean-mass problem in our muscle guide.

What it means for buyers now

Three practical readings. Waiting for the pipeline is rarely rational — approved, effective therapy exists today, and next-generation drugs launch at premium prices, not discounts. Price pressure flows downhill — each launch pushes incumbents toward the $299–$449 self-pay band and below, a dynamic already visible in the 2025–2026 cuts. And the compounded market's long-term position narrows structurally: cheap approved orals attack its price advantage from above while the regulatory picture contracts it from below. Every current price these futures will move is dated and tracked in the database.